| Literature DB >> 31993837 |
G Gallo1,2, J Martellucci3, A Sturiale4, G Clerico2, G Milito5, F Marino6, G Cocorullo7, P Giordano8, M Mistrangelo9, M Trompetto10.
Abstract
Hemorrhoidal disease (HD) is the most common proctological disease in the Western countries. However, its real prevalence is underestimated due to the frequent self-medication.The aim of this consensus statement is to provide evidence-based data to allow an individualized and appropriate management and treatment of HD. The strategy used to search for evidence was based on application of electronic sources such as MEDLINE, PubMed, Cochrane Review Library, CINAHL, and EMBASE.These guidelines are inclusive and not prescriptive.The recommendations were defined and graded based on the current levels of evidence and in accordance with the criteria adopted by American College of Chest Physicians. The recommendations were graded A, B, and C.Entities:
Keywords: Conservative treatment; Hemorrhoidal disease; Hemorrhoids; Office-based procedures; Postoperative complications; Special conditions; Surgical treatment
Mesh:
Year: 2020 PMID: 31993837 PMCID: PMC7005095 DOI: 10.1007/s10151-020-02149-1
Source DB: PubMed Journal: Tech Coloproctol ISSN: 1123-6337 Impact factor: 3.781
Grades of recommendation, assessment, development, and evaluation system grading recommendations
| Description | Benefit vs risk and burdens | Methodological quality of supporting evidence | Implications | |
|---|---|---|---|---|
| 1A | Strong recommendation, high-quality evidence | Benefits clearly outweigh risk and burdens or vice versa | RCTs without important limitations or overwhelming evidence from observational studies | Strong recommendation, can apply to most patients in most circumstances without reservation |
| 1B | Strong recommendation, moderate-quality evidence | Benefits clearly outweigh risk and burdens or vice versa | RCTs with important limitations (inconsistent results, methodological flaws, indirect or imprecise) or exceptionally strong evidence from observational studies | Strong recommendation, can apply to most patients in most circumstances without reservation |
| 1C | Strong recommendation, low- or very-low-quality evidence | Benefits clearly outweigh risk and burdens or vice versa | Observational studies or case series | Strong recommendation but may change when higher quality evidence becomes available |
| 2A | Weak recommendation, high-quality evidence | Benefits closely balanced with risks and burdens | RCTs without important limitations or overwhelming evidence from observational studies | Weak recommendation, best action may differ depending on circumstances or patient or societal values |
| 2B | Weak recommendations, moderate-quality evidence | Benefits closely balanced with risks and burdens | RCTs with important limitations (inconsistent results, methodological flaws, indirect or imprecise) or exceptionally strong evidence from observational studies | Weak recommendation, best action may differ depending on circumstances or patients’ or societal values |
| 2C | Weak recommendation, low- or very-low-quality evidence | Uncertainty in the estimates of benefits, risks, and burden; benefits, risks, and burden may be closely balanced | Observational studies or case series | Very weak recommendations; other alternatives may be equally reasonable |
RCTs Randomized-controlled trials